RAF1 and metastatic melanoma: Recently, the application of compounds targeting components of the MAPK pathway (such as RAF and MEK inhibitors) has been proven to substantially improve the clinical outcome of metastatic melanoma and can also show surprising clinical effects in other tumors [32].